To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
A New Chapter for Aelis Farma - Inauguration of New Headquarters in the Center of Bordeaux
December 2023
+
Aelis Farma announces positive results of non-clinical studies required by regulatory agencies to enter its first CB1-SSi, AEF0117, in phase 3 clinical trial...